Immunomodulators in asthma therapy

Current Allergy and Asthma Reports

Volumn 9, Issue 6, 2009, Pages 475-483

  Dimov, Vesselin V ^b   Stokes, Jeffrey R ^a   Casale, Thomas B ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1018; 1018 ISS; AEROVANT; ALTRAKINCEPT; AMG 317; ANTISENSE OLIGONUCLEOTIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHEMOKINE RECEPTOR CCR3; CORTICOSTEROID; CPG OLIGODEOXYNUCLEOTIDE; CYT 003 QBG 10; CYTOKINE RECEPTOR ANTAGONIST; DACLIZUMAB; GOLIMUMAB; IMMUNOMODULATING AGENT; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 4 RECEPTOR ALPHA ANTAGONIST; KETOTIFEN; LONG ACTING DRUG; MEPOLIZUMAB; PLACEBO; PREDNISONE; RAGWEED ANTIGEN; RESLIZUMAB; SHORT ACTING DRUG; SUPLATAST TOSYLATE; TOLAMBA; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TPI ASM 8; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ADAPTIVE IMMUNITY; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EOSINOPHILIA; FOOD ALLERGY; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INFECTION; INNATE IMMUNITY; LOADING DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; NEBULIZATION; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; WHEEZING;

ASTHMA; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, CYTOKINE; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME;

EID: 70350144847     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-009-0070-x     Document Type: Review

References (55)

1. Casale TB, Stokes JR: Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008, 121:288-296.
2. Fiedler G: Long-term efficacy of short course subcutaneous immunotherapy containing monophosphoryl lipid A adjuvant administered in a clinical setting [abstract P1769]. Allergy 2008, 63:612-621.
3. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484.
4. Bhattacharjee RN, Akira S: Modifying Toll-like receptor 9 signaling for therapeutic use. Mini Rev Med Chem 2006, 6:287-291.
5. Hayashi R, Raz E: TLR9-based immunotherapy for allergic disease. Am J Med 2006, 119:897,e1-e6.
6. Kline JN: Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc 2007, 4:283-288.
7. Higgins D, Rodriquez R, Milley R, et al.: Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1. J Allergy Clin Immunol 2006, 118:504-510.
8. Creticos PS, Shroeder JT, Hamilton RG, et al.: Immunotherapy with ragweed-toll-like receptor agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355:1445-1455.
9. Tulic MK, Fiset PO, Christodoulopoulos P, et al.: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004, 113:235-241.
10. Gauvreau GM, Hessel EM, Boulet LP, et al.: Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006, 174:15-20.
11. Blaziene A: CYT003-QbG10, a novel allergen-independent immunotherapy, shown to be safe and efficacious in placebo-controlled phase II study [abstract 19]. Presented at the Annual Meeting of the American College of Allergy, Asthma and Immunology. Seattle, WA; November 6-11, 2008.
12. Lamkhioued B, Soussi Gounni A, Hamid Q, et al.: The CCR-3 receptor is involved in eosinophil differentiation and is upregulated by TH2 cytokines in CD341 progenitor cells. J Immunol 2003, 170:537-547.
13. Martinez-Moczygemba M, Huston DP: Biology of common B receptor-signaling cytokines: IL-3, IL-5 and GM-CSF. J Allergy Clin Immunol 2003, 112:653-665.
14. Gauvreau GM, Boulet LP, Cockcroft DW, et al.: Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177:952-958.
15. Ishiura Y, Fujimura M, Yamamoto H, et al.: Effect of an orally active Th2 cytokine inhibitor, suplatast on "atopic cough" tosilate. Arzneimittelforschung 2008, 58:297-302.
16. Agrawal DK, Cheng G, Kim MJ, Kiniwa M: Interaction of suplatast tosilate (IPD) with chloride channels in human blood eosinophils: A potential mechanism underlying its anti-allergic and anti-asthmatic effects. Clin Exp Allergy 2008, 38:305-312.
17. Tanaka A, Minoguchi K, Samson KT, et al.: Inhibitory effects of suplatast tosilate on the differentiation and function of monocyte-derived dendritic cells from patients with asthma. Clin Exp Allergy 2007, 37:1083-1089.
18. Yoshihara S, Ono M, Yamada Y, et al.: Early intervention with suplatast tosilate for prophylaxis of pediatric atopic asthma: A pilot study. Pediatr Allergy Immunol 2009 Jan 30 (Epub ahead of print).
19. Borish LC, Nelson HS, Corren J, et al.: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107:963-970.
20. Haldar P, Brightling CE, Hargadon B, et al.: Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
21. Nair P, Pizzichini MM, Kjarsgaard M, et al.: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
22. Walsh GM: Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther 2009, 11:329-336.
23. Borowski A, Kuepper M, Horn U, et al.: Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts. Clin Exp Allergy 2008, 38:619-628.
24. Blanchard C, Mishra A, Saito-Akei H, et al.: Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy 2005, 35:1096-1103.
25. Bree A, Schlerman FJ, Wadanoli M, et al.: IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 2007, 119:1251-1257.
26. MedImmune Cambridge (formerly Cambridge Antibody Technology): MedImmune advances asthma program with start of a phase 2 trial in Europe and Australia and first U.S.-based clinical trial for antibody targeting IL-13. http://phx.corporate-ir.net/phoenix.zhtml?c=83037&p= irolinvestornewsArticle&ID=1129725&highlight=. Accessed August 28, 2009.
27. Blease K: Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling. Curr Opin Investig Drugs 2008, 9:1180-1184.
28. Corren J, Busse W, Meltzer E, et al.: Efficacy and safety of AMG 317, an IL-4Ra antagonist, in atopic asthmatic subjects: A randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2009, 123:732.
29. Aerovance: Aerovance announces positive top-line results from phase 2a trial of inhaled AEROVANT in asthma patients. Available at http://www.aerovance.com/news/press-releases/Press-Releases/ Aerovance-Announces-Positive-Top-Line-Results-from-Phase-2a-Trial-of- Inhaled-AEROVANT-in-Asthma-Patients-88, Accessed August 28, 2009.
30. Aerovance: Aerovance announces phase IIb clinical trial with AEROVANT for the treatment of uncontrolled asthma. Available at http://www.aerovance.com/news/press-releases/Press-Releases/ Aerovance-Initiates-Phase-IIb-Clinical-Trial-with-AEROVANT-for-the- Treatment-of-Uncontrolled-Asthma-80, Accessed August 28, 2009
31. Busse WW, Israel E, Nelson HS, et al.; Daclizumab Asthma Study Group: Daclizumab improves asthma control in patients with moderate to severe persistent asthma: A randomized, controlled trial. Am J Respir Crit Care Med 2008, 178:1002-1008.
32. Wenzel SE, Barnes PJ, Bleecker ER, et al.; T03 Asthma Investigators: A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179:549-558.
33. Barnes PJ: Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 2006, 109:238-245.
34. Rigel Pharmaceuticals: Rigel announces initiation of phase 1 trial of R343 for allergic asthma by its partner Pfizer [press release]. Available at http://ir.rigel.com/phoenix.zhtml?c=120936&p= irol-newsArticle&ID=1084738. Accessed June 12, 2009.
35. Meltzer EO, Berkowitz RB, Grossbard EB: An intranasal syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005, 115:791-796.
36. Spears M, McSharry C, Thomson NC: Peroxisome proliferator-activated receptor gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 2006, 36:1494-1504.
37. Belvisi MG, Hele DJ: Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest 2008, 134:152-157.
38. ClinicalTrials.gov: The use of rosiglitazone to treat asthma. Available at http://clinicaltrials.gov/ct2/show/NCT00614874. Accessed June 12, 2009.
39. ClinicalTrials.gov: Pioglitazone hydrochloride to treat asthma. Available at http://clinicaltrials.gov/ct2/show/NCT00604578. Accessed June 12, 2009.
40. Lin H, Boesel K, Griffith D, et al.: Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004, 113:297-302.
41. van Rensen EL, Evertse CE, van Schadewijk WA, et al.: Eosinophils in bronchial mucosa of asthmatics after allergen challenge: Effect of anti-IgE treatment. Allergy 2009, 64:72-80.
42. Busse W, Corren J, Lanier BQ, et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-190.
43. Milgrom H, Berger W, Nayak A, et al.: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001, 108:e36.
44. Soler M, Matz J, Townley R, et al.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254-261.
45. Corren J, Casale TB, Deniz Y, Ashby M: Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003, 111:87-90.
46. Berger W, Ostrom N, Soler M, et al.: Omalizumab significantly reduces asthma exacerbations in patients with severe persistent asthma: A pooled analysis. J Allergy Clin Immunol 2005, 115:S75.
47. National Asthma Education and Prevention Program: Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 3. Bethesda, MD: National Institutes of Health/National Heart, Lung, and Blood Institute; 2007. [Publication no. 08-4051.] Available at http://www.nhlbi.nih.gov/ guidelines/asthma.
48. Holgate ST, Chuchalin AG, Hebert J, et al.: Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632.
49. Johansson A, Nopp H, Öman J, et al.: The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. Allergy 2009 Apr 14 (Epub ahead of print).
50. Wu AC, Paltiel AD, Kuntz KM, et al.: Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model. J Allergy Clin Immunol 2007, 120:1146-1152.
51. Xolair [package insert]. South San Francisco, CA: Genentech; East Hanover, NJ: Novartis; 2008.
52. US Food and Drug Administration: Omalizumab (marketed as Xolair). Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm085291.htm. Accessed August 28, 2009.
53. Limb SL, Starke PR, Lee CE, Chowdhury BA: Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007, 120:1378-1381.
54. Corren J, Casale TB, Lanier B, et al.: Safety and tolerability of omalizumab. Clin Exp Allergy 2009, 39:788-797.
55. Cox L, Platts-Mills TAE, Finegold I, et al.: American Academy of Allergy Asthma & Immunology/American College of Allergy, Asthma and Immunology Task Force Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007, 120:1373-1377.